Business
Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer
CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing
About this update from Intellia Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Derek Hicks to a newly created position as Executive Vice President, Chief Business Officer. Mr. Hicks joins Intellia with more than 25 years of combined business, leadership and biotechnology experience, having most recently served as Head of Business Development at Spark Therapeutics. While at Spark, he was responsible for business development strategy, search and evaluation, licensing and key partnership activities. Prior to this role, Mr. Hicks spent 18 years at Pfizer in a variety of business and corporate development roles culminating with his position as Vice President, Corporate Development, World-Wide Business Development. “As Intellia continues to expand its leadership position in the field of genome editing, our ability to grow our pipeline, imagine new therapeutic possibilities and collaborate with leading organizations will be key to our future success. I am thrilled to welcome Derek to Intellia’s executive team as we enter the next chapter in our evolution,” said Intellia President and Chief Executive Officer John Leonard, M.D. “Derek is an accomplished business leader who shares Intellia’s values and commitment to bringing forth life-changing therapies for patients. He has a long, successful history of leading corporate and business development efforts in the biotechnology and pharmaceutical industry. I am confident his expertise will complement Intellia’s strong legacy of identifying and executing upon value-adding partnerships and corporate development opportunities critical to our mission of building the industry’s most innovative genome editing company.” “I could not be more excited to join Intellia at this transformational time as the team is just beginning to realize the full potential of genome editing,” said Mr. Hicks. “Intellia has clearly been a pioneer in the space, and I look forward to working with the Intellia team and our partners in maximizing the impact of its world-class science for the benefit of patients.” Mr. Hicks earned both a Bachelor’s and Master’s of Science degree in mechanical engineering from the University of Connecticut and a...